drugset / Trial / NCT06848556
Evaluate the Effect of Tirazamine on Primary Liver Cancer.
RandomizedParallel-groupOpen-labelTreatment
Summary
This Phase I/II trial aims to evaluate the pharmacokinetics, efficacy, and safety of tirapazamine administered via hepatic artery injection followed by TACE in patients with intermediate-stage HCC. The trial will compare the outcomes of TATE with standard TACE.
Timeline
- Start
- 2021-05-14
- Primary completion
- 2023-11-06
- Completion
- 2023-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tirapazamine | Small molecule | 5 mg/m2 | Other |
| Subject | tirapazamine | Small molecule | 10 mg/m2 | Other |
| Subject | tirapazamine | Small molecule | 20 mg/m2 | Other |
| Subject | tirapazamine | Small molecule | 35 mg | Other |